Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.47 |
| ▸ | HTR1D | P28221 | 13/20 | 0.45 |
| ▸ | HTR1B | P28222 | 10/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1F | P30939 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5350156 | 0.91 | HTR1D (0.46) | CCR2HTR1DHTR1BCHRM2DRD2 | |
| SCHEMBL5352711 | 0.91 | CCR2 (0.53) | CCR2 | |
| SCHEMBL5357679 | 0.90 | HTR1D (0.46) | HTR1DHTR1BCHRM2DRD2HSD11B1 | |
| SCHEMBL5354354 | 0.89 | HTR1D (0.45) | CCR2HTR1DHTR1BCHRM2DRD2 | |
| SCHEMBL5349966 | 0.89 | CCR2 (0.47) | CCR2HTR1DHTR1BCHRM2DRD2 | |
| SCHEMBL5369254 | 0.88 | CCR2 (0.40) | CCR2HTR1DHTR1BDRD2HTR1A | |
| SCHEMBL5361911 | 0.85 | KMT2A (0.49) | CCR2HTR1DHTR1BDRD2HSD11B1 | |
| SCHEMBL5325741 | 0.85 | DRD2 (0.40) | CCR2DRD2HSD11B1 | |
| SCHEMBL5345720 | 0.84 | KMT2A (0.49) | CCR2HTR1DHTR1BDRD2 | |
| SCHEMBL5349167 | 0.83 | KMT2A (0.50) | CCR2HTR1DHTR1BDRD2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007130712-A1 | SUBSTITUTED DIPIPERIDINE AS CCR2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA, NV (BE) | 2007-11-15 | — | — | WO | claimed |
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | claimed |
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | CCR2, CCR1, CCR5 | CCR2 1/4885HTR1D 804/4885HTR1B 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.